Abstract
Chronic lymphocytic leukemia (CLL) is a heterogeneous disease with alterations in genetic expression and epigenetic modifications. In recent years, the new insight into epigenetics in the pathogenesis of CLL has been developed considerably, including DNA methylation, histone modification, RNA methylation, non-coding RNAs as well as chromatin remodeling. Epigenetic modification regulates various processes such as stem cell biology, cell growth, and tumorigenesis without altering gene sequence. Growing evidence indicates that the disturbance of gene expression profiles which were regulated by epigenetic modifications exerts vital roles in the development and progress in CLL, which provides novel perspectives to explore the etiology of CLL. In addition, the integration with epigenetic therapeutic targets and the in-depth understanding of epigenetic therapy contribute to develop new therapeutic strategies for CLL. Herein, the present review discusses the advances of epigenetic alterations in the pathogenesis, diagnosis, and prognostic assessment of CLL patients and also highlights existing and emerging agents targeting epigenetic regulators.
Funding Information
  • China Postdoctoral Science Foundation (No. 2022M721981)
  • Shandong Provincial Natural Science Foundation (No.ZR2020QH094)
  • National Natural Science Foundation (No.82000195, No.82270200, No.82070203 and No.81770210)
  • Taishan Scholars Program of Shandong Province (No.tsqn201909184, No.tsqn201909184)
  • Key Research and Development Program of Shandong Province (No.2018CXGC1213)
  • Translational research grant of NCRCH (No.2021WWB02, No.2020ZKMB01)
  • Shandong Provincial Engineering Research Center of Lymphoma
  • Academic promotion programme of Shandong First Medical University (No.2019QL018)

This publication has 115 references indexed in Scilit: